# A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

> **NCT00578825** · NA · UNKNOWN · sponsor: **Hospital Authority, Hong Kong** · enrollment: 340 (estimated)

## Conditions studied

- Severe Acute Respiratory Syndrome

## Interventions

- **DRUG:** Lopinavir / Ritonavir plus Ribavirin

## Key facts

- **NCT ID:** NCT00578825
- **Lead sponsor:** Hospital Authority, Hong Kong
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2013-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00578825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00578825, "A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00578825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*